Market Overview - On September 24, the medical services sector declined by 2.01%, with Nanmo Biology leading the drop [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Individual Stock Performance - Bid Medicine (688073) saw a closing price of 74.63, with a gain of 5.74% and a trading volume of 13,300 hands, totaling a transaction value of 98.38 million [1] - Tiger Medical (300347) closed at 61.00, up 5.54%, with a trading volume of 150,500 hands and a transaction value of 908 million [1] - Guangzheng Eye Hospital (002524) closed at 4.23, up 4.44%, with a trading volume of 189,200 hands and a transaction value of 78.72 million [1] - Nanmo Biology (688265) closed at 52.35, down 1.75%, with a trading volume of 11,300 hands and a transaction value of 59.06 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 318 million from institutional investors and 117 million from retail investors, while retail investors saw a net inflow of 434 million [2][3] - Tiger Medical (300347) had a net inflow of 10.8 million from institutional investors but a net outflow of 9.19 million from retail investors [3] - Eye Care (300015) recorded a net inflow of 37.33 million from institutional investors, while retail investors had a net outflow of 41.60 million [3]

Core Points - The company, Nanmo Biology, announced the election of Wang Jinjing as the employee representative director for its fourth board of directors during a recent employee representative meeting [2] Summary by Category - **Corporate Governance** - The employee representative meeting approved the proposal to elect Wang Jinjing as the employee representative director [2]

证券代码：688265 证券简称：南模生物 公告编号：2025-061 上海南方模式生物科技股份有限公司 关于选举第四届董事会职工代表董事的公告 根据《公司章程》的规定，公司董事会由 11 名董事组成（包括 4 名独立董 事、1 名职工代表董事），其中 10 名股东代表董事由公司股东大会选举产生，1 名职工代表董事由公司职工通过职工代表大会民主选举产生。本次职工代表大会 选举产生的职工代表董事，将与公司 2025 年第二次临时股东大会选举产生的股 东代表董事共同组成公司第四届董事会，任期与公司第四届董事会一致。 特此公告。 上海南方模式生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海南方模式生物科技股份有限公司（以下简称"公司"或"南模生物"） 于 2025 年 9 月 23 日召开 2025 年第二次临时股东大会审议通过了《关于调整董 事会席位、取消监事会并修订<公司章程>的议案》，根据修订后的《上海南方模 式生物科技股份有限公司章程》（2025 年 5 月修订）（以下简称"《公司章程》"） 规 ...

证券代码：688265 证券简称：南模生物 公告编号：2025-060 上海南方模式生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：有 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 57 | | --- | --- | | 普通股股东人数 | 57 | | 2、出席会议的股东所持有的表决权数量 | 58,958,601 | | 普通股股东所持有表决权数量 | 58,958,601 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 77.9698 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 77.9698 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长费俭先生主持，采取现场投票和网 （ ...

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：上海南方模式生物科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共和国 公司法》（以下简称"《公司法》"）和中国证券监督管理委员会（以下简称"中国 证监会"）《上市公司股东会规则》等法律、法规、规章和其他规范性文件以及《上 海南方模式生物科技股份有限公司章程》（以下简称"《公司章程》"）的要求，上 海市锦天城律师事务所（以下简称"本所"）接受上海南方模式生物科技股份有限公 司（以下简称"南模生物"或"公司"）的委托，指派本所律师参加南模生物 2025 年第 二次临时股东大会（以下简称"本次股东大会"），就本次股东大会的有关事宜并出 具 ...

Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

Group 1 - The core point of the article highlights the performance and financial metrics of Nanmo Biotechnology, which saw a stock price increase of 5.71% to 57.24 CNY per share, with a total market capitalization of 4.463 billion CNY [1] - Nanmo Biotechnology specializes in the research, production, and sales of genetically modified animal models, with its main revenue sources being standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and other services (0.91%) [1] - The company is located in Shanghai and was established on September 20, 2000, with its listing date on December 28, 2021 [1] Group 2 - Among the top shareholders of Nanmo Biotechnology, the Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) reduced its holdings by 150,000 shares in the second quarter, now holding 800,000 shares, which represents 1.03% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 2.074 billion CNY and has achieved a year-to-date return of 20.36%, ranking 4289 out of 8244 in its category [2] - The fund has delivered a one-year return of 44.25%, ranking 3678 out of 8066, and a cumulative return of 190.8% since its inception on December 25, 2014 [2]

Market Overview - On September 18, the medical services sector declined by 1.68%, with Nanmo Biology leading the drop [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - Notable gainers included: - Zenggansi (301257) with a closing price of 53.80, up 6.89% [1] - Yangguang Nuohuo (688621) at 79.58, up 1.38% [1] - Kanglong Huacheng (300759) at 35.70, up 0.59% [1] - Major decliners included: - Nanmo Biology (688265) at 56.16, down 5.93% [2] - Chuangxin Medical (002173) at 23.48, down 4.75% [2] - Hongbo Pharmaceutical (301230) at 36.12, down 4.06% [2] Capital Flow - The medical services sector experienced a net outflow of 2.099 billion yuan from institutional investors, while retail investors saw a net inflow of 1.474 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment among different investor types [2] Individual Stock Capital Flow - Notable capital flows included: - Huada Gene (300676) with a net inflow of 63.2761 million yuan from institutional investors [3] - Baicheng Pharmaceutical (301096) with a net inflow of 21.5534 million yuan from institutional investors [3] - Nanmo Biology (688265) saw a net outflow of 1.597 million yuan from institutional investors [3]

2025 年第二次临时股东大会会议资料 公司代码：688265 公司简称：南模生物 上海南方模式生物科技股份有限公司 2025 年第二次临时股东大会会议资料 二〇二五年九月 1 2025 年第二次临时股东大会会议资料 目 录 | 2025 年第二次临时股东大会会议须知 3 | | | | --- | --- | --- | | 2025 年第二次临时股东大会投票议程 5 | | | | 议案一 关于调整董事会席位、取消监事会并修订《公司章程》的议案 | | 8 | | 议案二 关于修订公司治理相关制度的议案 | | 54 | | 议案三 关于第四届董事薪酬的议案 | | 55 | | 议案四 关于要求董事会制定公司未来三年的经营方针、投资计划和公司业务发 | | | | 展目标和规划的议案 | | 56 | | 议案五 关于充分抓住生物医药产业战略发展机遇，打造平台型企业，挖掘公司 | | | | 价值第二增长曲线，要求董事会制定相应行动计划的议案 | | 57 | | 议案六 关于保持公司现有核心管理层稳定，持续引进优秀人才的议案 | | 59 | | 议案七 关于要求公司进一步提升公司治理水平、加强与股东 ...

Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]